Stigma and political short-termism pose significant challenges to the implementation of lung cancer screening programs across Europe, according to Annemiek Snoeckx, MD, PhD, an expert in thoracic imaging and lung cancer screening.
Despite advancements in technology, Snoeckx highlights that stigma surrounding lung cancer remains one of the most persistent obstacles in promoting screening initiatives. Alongside this, issues related to smoking cessation and pressure on healthcare budgets complicate the situation. “Prevention also carries a particular political challenge: its benefits often emerge over years, while political decision-making tends to operate over much shorter cycles,” she explained.
Snoeckx emphasized that the existing evidence for the effectiveness of lung cancer screening should not serve as a reason for delaying its implementation. “Unresolved questions should not become an argument for postponing screening. The scientific evidence is established, policy support is developing, and implementation is already underway in many parts of Europe,” she stated.
Moving forward, the focus will shift from proving that lung cancer screening saves lives to ensuring that healthcare systems can deliver these services at scale with consistent quality and equitable access. This transition is critical as regions continue to adopt and expand their screening programs.
Snoeckx is currently an Associate Professor at the University of Antwerp and chairs the Radiology Department at Antwerp University Hospital in Belgium. She leads the ZORALCS trial, aimed at evaluating lung cancer screening implementation in Flanders, and is a co-founder of the Flemish Lung Cancer Screening Taskforce. In addition, she serves as Vice President of the European Society of Thoracic Imaging (ESTI) and is the Academy Director for the European Diploma in Radiology.


